To overcome the historical issue of oncolytic viruses being sequestered by the liver, Accession re-engineers a human virus so it cannot infect any human cells. Only after this safety step is it re-targeted to infect only cancer cells, ensuring precise delivery and avoiding systemic side effects.

A key innovation in Antibody-Drug Conjugates (ADCs) is the 'tandem cleave' linker. This technology requires two separate events—one in the tumor microenvironment and another after internalization—to release the payload, improving stability and reducing systemic toxicity.

Unlike vaccines requiring a patient's immune system to generate antibodies, Cidara's CD388 is a long-acting antiviral drug. It provides direct, passive protection by targeting a non-mutating part of the flu virus, making it effective for the millions of people with weakened immune systems who don't respond well to traditional shots.

To overcome on-target, off-tumor toxicity, LabGenius designs antibodies that act like biological computers. These molecules "sample" the density of target receptors on a cell's surface and are engineered to activate and kill only when a specific threshold is met, distinguishing high-expression cancer cells from low-expression healthy cells.

To mitigate the severe toxicity of promising pan-RAS inhibitors, companies are adopting antibody-drug conjugate (ADC) technology. This marks a strategic expansion for ADCs, moving beyond traditional cytotoxic chemotherapy payloads to delivering highly specific targeted therapies, aiming to improve the therapeutic window of potent new drug classes.

Cytospire targets well-validated antigens like EGFR, which were previously 'undruggable' by CD3 engagers due to severe toxicity on healthy cells. Their gamma delta T-cell platform solves this by enabling 'context-dependent killing,' discriminating between tumor and healthy tissue. This safety profile could unlock a portfolio of solid tumor targets previously considered too dangerous for this drug class.

Accession's second product is a bispecific antibody that binds to all cancer cells. While this would be dangerously toxic if delivered systemically, their targeted virus delivery system ensures it is only produced inside the tumor. This strategy makes previously "undruggable" therapeutic concepts viable.

The modular complexity of Degrader Antibody Conjugates (DACs) is a key challenge. New platform companies like 3C Therapeutics are offering 'plug-and-play' backbones to standardize DAC construction, addressing the problem where attaching an antibody to an existing degrader negatively alters its essential properties.

Mini-proteins are framed as a superior drug modality that merges the key strengths of traditional therapies. They possess the high selectivity characteristic of biologics like antibodies, while also having the stability and formulation advantages of small-molecule drugs. This combination allows them to precisely target difficult receptors while avoiding common off-target effects or instability issues.